Compare Kyowa Kirin Co., Ltd. with Similar Stocks
Dashboard
1
The company has declared Negative results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Lowest at JPY 60,873 MM
- ROCE(HY) Lowest at 4.51%
- INTEREST(Q) At JPY 2,539 MM has Grown at 1,700.71%
2
With ROE of 6.08%, it has a very attractive valuation with a 1.56 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,349,304 Million (Large Cap)
26.00
NA
0.04%
-0.28
4.32%
1.59
Revenue and Profits:
Net Sales:
125,929 Million
(Quarterly Results - Jun 2025)
Net Profit:
10,153 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.97%
0%
0.97%
6 Months
-6.5%
0%
-6.5%
1 Year
6.59%
0%
6.59%
2 Years
3.89%
0%
3.89%
3 Years
-16.64%
0%
-16.64%
4 Years
-17.04%
0%
-17.04%
5 Years
-24.92%
0%
-24.92%
Kyowa Kirin Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.99%
EBIT Growth (5y)
9.37%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.56
Tax Ratio
30.50%
Dividend Payout Ratio
51.30%
Pledged Shares
0
Institutional Holding
0.13%
ROCE (avg)
16.11%
ROE (avg)
7.78%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.56
EV to EBIT
12.74
EV to EBITDA
9.81
EV to Capital Employed
1.75
EV to Sales
2.19
PEG Ratio
NA
Dividend Yield
0.04%
ROCE (Latest)
13.76%
ROE (Latest)
6.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.13%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
125,929.00
127,404.00
-1.16%
Operating Profit (PBDIT) excl Other Income
30,149.00
30,999.00
-2.74%
Interest
2,539.00
729.00
248.29%
Exceptional Items
0.00
-434.00
100.00%
Consolidate Net Profit
10,153.00
23,144.00
-56.13%
Operating Profit Margin (Excl OI)
190.00%
192.60%
-0.26%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -1.16% vs 20.56% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -56.13% vs 160.45% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
495,558.00
442,233.00
12.06%
Operating Profit (PBDIT) excl Other Income
116,646.00
116,938.00
-0.25%
Interest
709.00
190.00
273.16%
Exceptional Items
-15,135.00
-5,213.00
-190.33%
Consolidate Net Profit
59,870.00
81,188.00
-26.26%
Operating Profit Margin (Excl OI)
185.40%
216.70%
-3.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 12.06% vs 11.01% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -26.26% vs 51.55% in Dec 2023
About Kyowa Kirin Co., Ltd. 
Kyowa Kirin Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






